Phocas Financial’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-71,197
Closed -$1.83M – 47
2026
Q2
$1.83M Buy
+71,197
New +$1.46M 0.25% 117

Other funds holding DNLI

Phocas Financial's DNLI Position: Q3 2026 in Review

Phocas Financial sold out of Denali Therapeutics (DNLI) in Q3 2026, closing a stake of 71,197 shares — an estimated $1.83M sold.

Phocas Financial first reported a position in DNLI in Q2 2026 and held it in 1 quarter. The position peaked at $1.83M in Q2 2026. 286 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Phocas Financial reported no remaining Denali Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Phocas Financial sold 71,197 Denali Therapeutics shares in Q3 2026, an estimated $1.83M.
  • Phocas Financial first reported a position in Denali Therapeutics in Q2 2026 and held it in 1 quarter.
  • Phocas Financial's Denali Therapeutics position peaked at $1.83M in Q2 2026.
  • 286 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Phocas Financial's 13F filing for Q3 2026.